Novartis Blocked From Selling Neupogen Copycat Until Sept. 2Novartis Blocked From Selling Neupogen Copycat Until Sept. 2

Novartis AG unit Sandoz must wait until Sept. 2 to sell Zarxio (filgrastim-sndz), the first biosimilar drug to be approved in the United States and a copycat version of Amgen Inc's $1.2 billion-a-year anti-infection drug Neupogen (filgrastim), a U.S. appeals court said on Tuesday. Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Infectious Diseases News Source Type: news